Drug Profile
Research programme: ceNOS gene therapy - Crucell/BIOA&D
Latest Information Update: 16 Jun 2011
Price :
$50
*
At a glance
- Originator BIOA&D; Crucell
- Class
- Mechanism of Action Gene transference; Nitric oxide donors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cardiovascular disorders
Most Recent Events
- 30 May 2006 Preclinical trials in Cardiovascular disorders in Netherlands (unspecified route)